ORTHO-NOVUM 7/7/7-21
Clinical safety rating
cautionComprehensive clinical and safety monograph for ORTHO-NOVUM 7/7/7-21 (ORTHO-NOVUM 7/7/7-21).
Combined hormonal contraceptive; primarily suppresses ovulation via inhibition of gonadotropin release (LH and FSH) from the pituitary. Also induces changes in cervical mucus and endometrium.
| Metabolism | Metabolized primarily by CYP3A4; norethindrone undergoes reduction and conjugation; ethinyl estradiol undergoes hydroxylation and glucuronidation. |
| Excretion | Renal: <10% unchanged; biliary/fecal: ~50% as metabolites; extensive enterohepatic recirculation. |
| Half-life | Ethinyl estradiol: 13-27 hours; norethindrone: 8-14 hours; with multiple dosing, steady state after 5-7 days. |
| Protein binding | Ethinyl estradiol: 95-98% bound to albumin and SHBG; norethindrone: 60-70% bound to SHBG and albumin. |
| Volume of Distribution | Ethinyl estradiol: 2.5-4 L/kg; norethindrone: 3.5-5 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: ~40-50% for ethinyl estradiol (first-pass metabolism); ~60-70% for norethindrone. |
| Onset of Action | Oral: contraceptive effect requires 7 days of consistent dosing; peak hormone levels at 1-2 hours. |
| Duration of Action | Oral: 24-hour dosing interval; contraceptive protection persists with each daily pill; withdrawal bleed during placebo week. |
| Molecular Weight | 340.46 |
One tablet orally once daily for 21 days, followed by 7 days of no tablets. Each tablet contains norethindrone 0.5 mg/0.75 mg/1 mg and ethinyl estradiol 35 mcg, with biphasic or triphasic dosing per cycle.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (GFR 30-89 mL/min). Not recommended for severe renal impairment (GFR <30 mL/min) due to potential fluid retention and electrolyte disturbances. |
| Liver impairment | Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; no specific dose adjustment, but monitor for signs of hepatic toxicity. |
| Pediatric use | Not indicated for use before menarche. Post-menarche adolescents: same dosing as adults. Weight-based adjustments not established; use standard adult regimen. |
| Geriatric use | Not indicated for postmenopausal women. Use in perimenopausal women: standard dosing with consideration of increased thrombotic risk and comorbidities. |
| 1st trimester | Contraindicated: Risk of teratogenicity, including neural tube defects, cardiovascular anomalies, and VACTERL association. Avoid use during first trimester. |
| 2nd trimester | Contraindicated: Potential for fetal harm, including feminization of male fetuses due to progestin activity. Generally avoided unless essential. |
| 3rd trimester | Contraindicated: Risk of adverse effects such as jaundice, cholestasis, and potential for delayed parturition. Not recommended. |
Clinical note
Comprehensive clinical and safety monograph for ORTHO-NOVUM 7/7/7-21 (ORTHO-NOVUM 7/7/7-21).
| Placental transfer | Norethindrone and ethinyl estradiol cross the placenta. Norethindrone is extensively bound and transferred; ethinyl estradiol shows significant placental passage. |
| Breastfeeding | Norethindrone and ethinyl estradiol are excreted in small amounts into breast milk. May reduce milk production and affect infant development. Use only if clearly needed and with caution, monitoring infant for jaundice and growth. AAP considers hormonal contraceptives compatible with breastfeeding after postpartum period, but combined OCs may decrease milk supply. |
| Lactation Rating | L3 (Moderately Safe) / Consider alternative |
| Teratogenic Risk | Combined hormonal contraceptives like ORTHO-NOVUM 7/7/7-21 are contraindicated in pregnancy. First trimester exposure is not associated with major malformations based on current data, but there is a small increased risk of cardiovascular and limb defects. Second and third trimester exposure has been associated with fetal harm including masculinization of female genitalia (due to progestin) and potential long-term effects. Use during pregnancy is not indicated; if pregnancy occurs, discontinue immediately. |
| Fetal Monitoring | Before initiating, rule out pregnancy. During use, monitor for signs of pregnancy if missed pills. No routine fetal monitoring required if not pregnant. If inadvertent use during pregnancy, consider ultrasound for fetal anatomy. |
| Fertility Effects | ORTHO-NOVUM 7/7/7-21 is used for contraception and reversibly suppresses ovulation. Return to fertility may be delayed up to a few months after discontinuation. No permanent effects on fertility. |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive use. This risk increases with age, especially in women over 35 years, and with the number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
| Serious Effects |
Current or history of venous or arterial thromboembolismCerebrovascular diseaseKnown or suspected pregnancyUndiagnosed abnormal uterine bleedingKnown or suspected estrogen-dependent neoplasiaHepatic adenoma or carcinomaActive liver disease or impaired liver functionCigarette smoking in women over 35 years of ageMigraine with focal aura at any ageHypersensitivity to any component
| Precautions | Thrombotic disorders (e.g., venous thromboembolism, stroke, myocardial infarction), Hepatic disease (e.g., jaundice, liver tumors), Hypertension, Carbohydrate and lipid metabolism effects, Headache/migraine, Bleeding irregularities, Depression, Gallbladder disease, Hereditary angioedema, Pregnancy and postpartum use, Ophthalmic complaints (contact lens intolerance, retinal thrombosis) |
| Food/Dietary | No significant food interactions. Grapefruit juice may increase estrogen exposure; avoid large amounts. Taking with food can reduce nausea. |
| Clinical Pearls | This triphasic oral contraceptive contains norethindrone and ethinyl estradiol. The 7/7/7-21 regimen uses three different hormone doses over 21 days followed by 7 placebo pills. Monitor for breakthrough bleeding, especially during dose transitions. Assess for contraindications including history of DVT, PE, migraine with aura, breast cancer, liver disease, or age >35 with smoking. Consider CYP3A4 interactions; rifampin, certain anticonvulsants, and St. John's wort may reduce efficacy. |
| Patient Advice | Take one pill daily at the same time; missing pills increases pregnancy risk. · Start pack on first day of period or first Sunday after; use backup contraception for first 7 days if starting later. · Common side effects: nausea, breast tenderness, breakthrough bleeding; usually improve within 3 cycles. · Do not smoke while taking this medication; smoking increases risk of serious cardiovascular side effects. · Seek emergency care if signs of blood clot: sudden leg pain/swelling, chest pain, shortness of breath, severe headache, vision changes. · Some medications (antibiotics, seizure meds, St. John's wort) may decrease effectiveness; inform all healthcare providers. |
Loading safety data…